関連する実験動画

Updated: May 12, 2026

Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction
07:41

Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction

Published on: June 7, 2011

選択的ターゲティングとマトリックスメタルプロテインアース阻害のタイミングは,心筋梗塞後のリモデリングにおける選択的ターゲティングとタイミングです

William M Yarbrough1, Rupak Mukherjee, G Patricia Escobar

  • 1Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, and Procter and Gamble Pharmaceuticals, Mason, Ohio, USA.

Circulation
|September 17, 2003
PubMed
まとめ

選択的マトリックス金属タンパク質酶 (MMP) 阻害により,MMP-1およびMMP-7は保存され,心筋梗塞 (MI) の後の左心室 (LV) の改造に好意的に影響を与えることができます. この選択的なMMP阻害 (sMMPi) のタイミングは,改造パターンに影響を与える.

さらに関連する動画

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

関連する概念動画

Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...